Keel Point LLC Takes $206,000 Position in Pfizer Inc. (NYSE:PFE)

Keel Point LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,152 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

Other institutional investors have also made changes to their positions in the company. Sippican Capital Advisors increased its stake in Pfizer by 37.7% in the 4th quarter. Sippican Capital Advisors now owns 68,144 shares of the biopharmaceutical company’s stock valued at $1,962,000 after buying an additional 18,657 shares during the period. Mackenzie Financial Corp increased its stake in shares of Pfizer by 39.8% in the fourth quarter. Mackenzie Financial Corp now owns 1,716,901 shares of the biopharmaceutical company’s stock worth $49,430,000 after acquiring an additional 488,479 shares during the last quarter. Warner Financial Inc. boosted its position in Pfizer by 4.2% during the fourth quarter. Warner Financial Inc. now owns 39,385 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 1,583 shares during the last quarter. Cullen Investment Group LTD. acquired a new position in Pfizer in the 4th quarter worth about $1,484,000. Finally, Conning Inc. raised its stake in shares of Pfizer by 13.4% during the 4th quarter. Conning Inc. now owns 1,208,125 shares of the biopharmaceutical company’s stock worth $34,715,000 after purchasing an additional 142,872 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of PFE stock opened at $25.41 on Thursday. The stock’s fifty day simple moving average is $27.19 and its 200 day simple moving average is $28.76. Pfizer Inc. has a one year low of $25.26 and a one year high of $41.33. The firm has a market cap of $143.86 billion, a price-to-earnings ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.